Edap Tms SA

Edap Tms SA has a market price of $4.13 and a market capitalization of $154.8 million, with a price-to-book ratio of 7.97 and a price-to-tangible-book ratio of 7.97. The company's liquidity position is characterized by $20.5 million in cash and equivalents, but it carries $24.6 million in long-term debt, resulting in a debt-to-equity ratio of 1.27 and a current ratio of 1.54. The company's negative operating cash flow of $16.4 million and free cash flow of $31.6 million indicate significant liquidity constraints. The company's profitability metrics are weak, with a net loss of $29.2 million and an operating loss of $24.7 million in the latest period. Return on equity is -150.65%, and return on assets is -37.02%, both significantly below industry norms for medical equipment firms. Gross profit of $30.0 million on $70.5 million in revenue yields a 42.5% gross margin, but this is insufficient to offset operating expenses. Edap Tms SA operates in a single business segment focused on HIFU systems, with no disclosed geographic revenue breakdown in the latest financials. The company's revenue concentration in a single product line and limited geographic diversification increases exposure to market-specific risks. The company's growth trajectory is uncertain, with no revenue growth data provided in the latest financials. Analysts have issued a mean price target of $5.50 and a median price target of $4.00, with a mean recommendation of 2.67 (leaning toward hold). The absence of strong buy ratings and the presence of two hold recommendations suggest limited near-term upside. The company faces medium liquidity risk due to negative net cash after subtracting total debt. Dilution risk is assessed as low, with no recent share issuance activity and no material dilution adjustments in the valuation model. The company's capital structure is highly leveraged, with total liabilities of $59.6 million against total equity of $19.4 million. Recent filings and transcripts show no material changes in the company's strategic direction or product pipeline. The company continues to focus on expanding its HIFU technology in urology and gynecology markets, but faces competition from established medical device firms.